Membranous nephropathy associated with chronic hepatitis B occurring in a short period after acute hepatitis B virus infection

Internal Medicine

Volumn 49, Issue 5, 2010, Pages 383-388

  Nakahara, Kazunari ^a   Takahashi, Hideaki ^a   Okuse, Chiaki ^a   Shigefuku, Ryuta ^a   Yamada, Norie ^a   Murao, Mei ^a   Matsunaga, Kotaro ^a   Koike, Junki ^a   Yotsuyanagi, Hiroshi ^b   Suzuki, Michihiro ^a   Kimura, Kenjiro ^a   Itoh, Fumio ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Genotype A; Hepatitis B virus; Membranous nephropathy

Indexed keywords

ALPHA INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; VIRUS DNA;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE EXACERBATION; GLOMERULONEPHRITIS; HEPATITIS B; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LABORATORY TEST; MALE; MEMBRANOUS GLOMERULONEPHRITIS; OUTPATIENT CARE; PROTEINURIA; REMISSION;

ACUTE DISEASE; ANTIVIRAL AGENTS; BIOPSY; GLOMERULONEPHRITIS, MEMBRANOUS; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; KIDNEY; MALE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77749333259     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.2812     Document Type: Article

References (47)

1. Lai KN, Li PK, Lui SF, et al. Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 324: 1457-1463, 1991.
2. McMahon BJ, Heyward WL, Templin DW, et al. Hepatitis Bassociated polyarteritis nodosa in Alaskan Eskimos: clinical and epidemiologic features and long-term follow-up. Hepatology 9: 97-101, 1989.
3. Levo Y, Gorevic PD, Kassab HJ, et al. Association between hepatitis B virus and essential mixed cryoglobulinemia. N Engl J Med 296: 1501-1504, 1977.
4. Lai KN, Lai FM, Tam JS. IgA nephropathy associated with chronic hepatitis B virus infection in adults: the pathogenetic role of HBsAG. J Pathol 157: 321-327, 1989.
5. Lai KN, Tam JS, Lin HJ, et al. The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenaemia. Nephron 54: 12-17, 1990.
6. Noto H, Terao T, Ryou S, et al. Combined passive and active immunoprophylaxis for preventing perinatal transmission of the hepatitis B virus carrier state in Shizuoka, Japan during 1980-1994. J Gastroenterol Hepatol 18: 943-949, 2003.
7. Kobayashi M, Arase Y, Ikeda K, et al. Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan. J Med Virol 68: 522-528, 2002.
8. Combes B, Shorey J, Barrera A, et al. Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane. Lancet 2: 234-237, 1971.
9. Ito H, Hattori S, Matusda I, et al. Hepatitis B e antigen-mediated membranous glomerulonephritis. Correlation of ultrastructural changes with HBeAg in the serum and glomeruli. Lab Invest 44: 214-220, 1981.
10. Hirose H, Udo K, Kojima M, et al. Deposition of hepatitis B e antigen in membranous glomerulonephritis: identification by F(ab')2 fragments of monoclonal antibody. Kidney Int 26: 229-241, 1984.
11. Seggie J, GNathoo K, Davies PG. Association of hepatitis B (HBs) antigenaemia and membranous glomerulonephritis in Zimbabwean children. Nephron 38: 115-119, 1984.
12. Lai KN, Lai FM, Chan KW, et al. The clinico-pathologic features of hepatitis B virus-associated glomerulonephritis. Q J Med 63: 323-333, 1987.
13. Lai KN, Lai FM, Tam JS, et al. High prevalence of hepatitis B surface antigenaemia in nephrotic syndrome in Hong Kong. Ann Trop Paediatr 9: 45-48, 1989.
14. Lin CY. Hepatitis B virus-associated membraneous nephropathy: clinical features, immunological profiles and outcome. Nephron 55: 37-44, 1990.
15. Coovadia HM, Adhikari M, Moodley D. Hepatitis B 's' and 'e' antigen carriage in childhood nephrotic syndrome predicts membranous glomerulonephritis. Ann Trop Paediatr 13: 79-82, 1993.
16. Gilbert RD, Wiggelinkhuizen J. The clinical course of hepatitis B virus-associated nephropathy. Pediatr Nephrol 8: 11-14, 1994.
17. Johnson RJ, Couser WG. Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations. Kidney Int 37: 663-676, 1990.
18. Lin CY. Clinical features and natural course of HBV-related glomerulopathy in children. Kidney Int Suppl 35: S46-S53, 1991.
19. Levy M, Kleinknecht C. Membranous glomerulonephritis and hepatitis B virus infection. Nephron 26: 259-265, 1980.
20. Bhimma R, Coovadia HM, Adhikari M. Hepatitis B virus-associated nephropathy in black South African children. Pediatr Nephrol 12: 479-484, 1998.
21. He XY, Fang LJ, Zhang YE, et al. In situ hybridization of hepatitis B DNA in hepatitis B-associated glomerulonephritis. Pediatr Nephrol 12: 117-120, 1998.
22. Bhimma R, Coovadia HM, Kramvis A, et al. Treatment of hepatitis B virus-associated nephropathy in black children. Pediatr Nephrol 17: 393-399, 2002.
23. Brzosko WJ, Krawczynski K, Nazarewicz T, et al. Glomerulonephritis associated with hepatitis-B surface antigen immune complexes in children. Lancet 2: 477-482, 1974.
24. Hsu HC, Lin GH, Chang MH, et al. Association of hepatitis B surface (HBs) antigenemia and membranous nephropathy in children in Taiwan. Clin Nephrol 20: 121-129, 1983.
25. Knecht GL, Chisari FV. Reversibility of hepatitis B virus-induced glomerulonephritis and chronic active hepatitis after spontaneous clearance of serum hepatitis B surface antigen. Gastroenterology 75: 1152-1156, 1978.
26. Ito H, Yoshikawa N, Aozai F, et al. Twenty-seven children with focal segmental glomerulosclerosis: correlation between the segmental location of the glomerular lesions and prognosis. Clin Nephrol 22: 9-14, 1984.
27. Lai KN, Lai FM, Tam JS, et al. Comparison of polyclonal and monoclonal antibodies in determination of glomerular deposits of hepatitis B virus antigens in hepatitis B virus-associated glomerulonephritides. Am J Clin Pathol 92: 159-165, 1989.
28. Bhimma R, Coovadia HM. Hepatitis B virus-associated nephropathy. Am J Nephrol 24: 198-211, 2004.
29. Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus - large-scale analysis using a new genotyping method. J Infect Dis 175: 1285-1293, 1997.
30. Orito E, Ichida T, Sakugawa H, et al. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 34: 590-594, 2001.
31. Sherlock S. The natural history of hepatitis B. Postgrad Med J 63: 7-11, 1987.
32. Kobayashi M, Arase Y, Ikeda K, et al. Clinical features of hepatitis B virus genotype A in Japanese patients. J Gastroenterol 38: 656-662, 2003.
33. Kobayashi M, Arase Y, Ikeda K, et al. Clinical characteristics of patients infected with hepatitis B virus genotypes A, B, and C. J Gastroenterol 37: 35-39, 2002.
34. Li JS, Tong SP, Wen YM, et al. Hepatitis B virus genotype A rarely circulates as an HBe minus mutant: Possible contribution of a single nucleotide in the precore region. J Virol 67: 5402-5410, 1993.
35. Kusakabe A, Tanaka Y, Kurbanov F, et al. Virological features of hepatitis B virus-associated nephropathy in Japan. J Med Virol 79: 1305-1311, 2007.
36. Conjeevaram HS, Hoofnagle JH, Austin HA, et al. Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa. Gastroenterology 109: 540-546, 1995.
37. Abbas NA, Pitt MA, Green AT, et al. Successful treatment of hepatitis B virus (HBV)-associated membranoproliferative glomerulonephritis (MPGN) with alpha interferon. Nephrol Dial Transplant 14: 1272-1275, 1999.
38. Al-Wakeel J, Mitwalli A, Tarif N, et al. Role of interferon-alpha in the treatment of primary glomerulonephritis. Am J Kidney Dis 33: 1142-1146, 1999.
39. Mesquita M, Lasser L, Langlet P. Long-term (7-year-) treatment with lamivudine monotherapy in HBV-associated glomerulonephritis. Clin Nephrol 70: 69-71, 2008.
40. Okuse C, Yotsuyanagi H, Yamada N, et al. Successful treatment of hepatitis B virus-associated membranous nephropathy with lamivudine. Clin Nephrol 65: 53-56, 2006.
41. Tang S, Lai KN. Hepatitis B-related membranous nephropathy should be treated with a specific anti-viral agent. Kidney Int 70: 818, 2006.
42. Di Marco V, De Lisi S, Li Vecchi M, et al. Therapy with lamivudine and steroids in a patient with acute hepatitis B and rapidly progressive glomerulonephritis. Kidney Int 70: 1187-1188, 2006.
43. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 119: 172-180, 2000.
44. Kobayashi M, Suzuki F, Akuta N, et al. Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C. J Med Virol 78: 1276-1283, 2006.
45. Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 54: 1009-1013, 2005.
46. Flink HJ, van Zonneveld M, Hansen BE, et al. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 101: 297-303, 2006.
47. Yotsuyanagi H, Okuse C, Yasuda K, et al. Distinct geographic distributions of hepatitis B virus genotypes in patients with acute infection in Japan. J Med Virol 77: 39-46, 2005.